Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

Phase II Study of E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma
eribulin mesIlate
E7389-E044-207
NCT00413192 EU CTR 2005-004272-20
Soft Tissue Sarcoma
Phase 2
 
No restrictions.
November 2017

Powered by ideaPoint, Inc.